He bites his tongue for no one
A profile to remember: CEO of and partner in NB Capital, Florian Schönharting, spoke to MedWatch about, not just the all-time high return of his investment fund, but also a politically controversial suggestion to let those medical patients that can afford it, pay for the best medicine available. He simply has to comment on misconceptions, he points out.
There must be very few pharmaceuticals on the market that 43-year-old Florian Schönharting does not have knowledge of. For more than 20 years he has been working with investments in the pharmaceutical world, first as Asset Manager in BankInvest Asset Management and later on as founder of and partner in Nordic Biotech, now known as NB Capital, which means that he has seen several conjuncture-turns, made his mistakes – and learned from them.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Biotech beats the general market in the long run
For abonnenter
